Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief (PIXAR)

September 22, 2026 updated by: The Archer-Daniels-Midland Company

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

101

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maharashtra
      • Pune, Maharashtra, India, Pune 411 041
        • Pulse Multispeciality Hospital,
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Atlantia Food Clinical Trials

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 weeks to 2 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Gestational age of minimum 37 weeks.
  • Birthweight of minimum 2500 g (5.5 lb.).
  • Age of greater than 3 weeks and less than 12 weeks at enrolment.
  • Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording >3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period & for duration of study).
  • Participant Informed Consent form signed by parent or legal guardian.
  • Infant is considered healthy following physical exam.
  • Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits

Exclusion Criteria:

  • Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
  • Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
  • Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
  • Failure to thrive.
  • Known lactose or gluten intolerance.
  • Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
  • Known other causes for abdominal pain (e.g., pyloric stenosis).
  • Participation in any other interventional clinical study.
  • Immuno-compromised participant or participant with other severe chronic disorder.
  • Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
  • Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
  • Any Participant/Parent/Caregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active

Arm receiving investigation product (probiotic)

Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks

Placebo Comparator: Placebo

Arm receiving placebo

Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cry and fuss time
Time Frame: Day 0, Day 28

eDiary parent reported cry and fuss time

Day 0, Day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cry and fuss time
Time Frame: Day 0, Day 7

eDiary parent reported cry and fuss time

Day 0, Day 7
Resolution of colic symptoms
Time Frame: Day 0, Day 28

Reduction of cry and fuss time (parent reported) greater than 90% comparing to baseline

Day 0, Day 28
Change in cry and fuss time bouts
Time Frame: Day 0, Day 7, Day 28

eDiary parent reported cry and fuss bouts

Day 0, Day 7, Day 28
Change in sleeping time
Time Frame: Day 0, Day 7, Day 28

eDiary parent reported sleep time

Day 0, Day 7, Day 28
Change in the use of rescue medications
Time Frame: Day 0, Day 28

Change in the proportion of participants needing to use rescue medications between the study arms

Day 0, Day 28

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in maternal quality of life and mental health
Time Frame: Day 0, Day 28

Change in maternal QoL using WHO QOL/BREF (improvement marked by increase in the total score)

Day 0, Day 28
Change in maternal quality of life and mental health
Time Frame: Day 0, Day 28

Change in maternal QoL using MAPP/QoL (improvement marked by increase in the total score)

Day 0, Day 28
Resolution of colic symptoms
Time Frame: Day 0, Day 28

Reduction of cry and fuss time (parent reported) greater than 50% comparing to baseline

Day 0, Day 28
Change in the use of rescue medication drops
Time Frame: Day 0, Day 7, Day 28

Change in the number of rescue medication drops used between the study arms

Day 0, Day 7, Day 28
Change in duration of daily crying and fussing episodes
Time Frame: Day 0, Day 7, Day 28

Change in mean duration per crying and fussing episode per day

Day 0, Day 7, Day 28
Changes in gut microbiome composition
Time Frame: Day 0, Day 28

Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline

Day 0, Day 28
Change in fecal calprotectin concentration
Time Frame: Day 0, Day 28

Changes in fecal calprotectin concentration throughout the study as compared to placebo and baseline

Day 0, Day 28
Adverse Events (AEs)
Time Frame: From enrolment to Day 35

Reports of Adverse Events (AEs) and Serious Adverse Events (SAEs)

From enrolment to Day 35
Change in vital signs
Time Frame: Day 0, Day 28

Changes in vital sign measurements (heart rate [bpm] and body temperature [°F]) collected during the study will be summarised by treatment group

Day 0, Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2022

Primary Completion (Actual)

April 15, 2026

Study Completion (Actual)

April 15, 2026

Study Registration Dates

First Submitted

June 21, 2022

First Submitted That Met QC Criteria

June 21, 2022

First Posted (Actual)

June 27, 2022

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PCTB202010

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.